Agios to Present at the Citi 13th Annual Biotech Conference Wednesday, September 5, 2018 Read more about Agios to Present at the Citi 13th Annual Biotech Conference Wednesday, September 5, 2018
Agios Pharmaceuticals at Citi 13th Annual Biotech Conference Read more about Agios Pharmaceuticals at Citi 13th Annual Biotech Conference
Agios Reports Second Quarter 2018 Financial Results Read more about Agios Reports Second Quarter 2018 Financial Results
Agios to Webcast Conference Call of Second Quarter 2018 Financial Results on August 2, 2018 Read more about Agios to Webcast Conference Call of Second Quarter 2018 Financial Results on August 2, 2018
FDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation Read more about FDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation
Q2 2018 Agios Pharmaceuticals Inc Earnings Conference Call Read more about Q2 2018 Agios Pharmaceuticals Inc Earnings Conference Call
Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China Read more about Agios and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Ivosidenib in Greater China
Agios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused Read more about Agios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused
New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients Read more about New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients
